GKWIM
PRVB

Gerber Kawasaki Wealth & Investment Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed -$3K – 1217
2021
Q3 		$3K Buy
+3
New +$19 ﹤0.01% 868

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's PRVB Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q4 2021, closing a stake of 3 shares — an estimated $3K sold.

Gerber Kawasaki Wealth & Investment Management first reported a position in PRVB in Q3 2021 and held it in 1 quarter. The position peaked at $3K in Q3 2021. 112 funds tracked by Wall St. Rank hold PRVB as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining Provention Bio, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 3 Provention Bio, Inc. Common Stock shares in Q4 2021, an estimated $3K.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in Provention Bio, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's Provention Bio, Inc. Common Stock position peaked at $3K in Q3 2021.
  • 112 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.